Organon & Co. - SIC # 2840 -

Ticker Exchange SIC # Website Latest Ticker
OGN New York 2840 www.organon.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Organon & Co.

Organon to Report Second Quarter 2026 Results in Its Regularly Scheduled Form 10-Q Filing - Jul 16th, 2026 5:30 am
Organon & Co. (OGN) Is a Trending Stock: Facts to Know Before Betting on It - Jul 15th, 2026 7:00 am
Organon to Present New Analysis on VTAMA® (tapinarof) cream, 1%, at the 2026 Society for Pediatric Dermatology Annual Meeting - Jul 7th, 2026 6:00 am
Investors Heavily Search Organon & Co. (OGN): Here is What You Need to Know - Jul 3rd, 2026 7:00 am
Can Organon & Co. (OGN)’s MIUDELLA Launch Become a Major Driver in Women’s Health Markets? - Jun 30th, 2026 7:08 am
2 Biotech Stocks Worth Buying Before Their Potential Buyouts - Jun 27th, 2026 12:05 pm
Organon Canada and Henlius Expand Access to Denosumab Treatments With Launch of BILDYOS® (denosumab injection) and TUZEMTY® (denosumab injection), Biosimilars to PROLIA and XGEVA - Jun 23rd, 2026 3:30 am
Organon & Co. (OGN) is Attracting Investor Attention: Here is What You Should Know - Jun 22nd, 2026 7:00 am
Organon Completes Agreement to License MIUDELLA®, Sebela Pharmaceuticals’ Hormone-Free Intrauterine Device - Jun 22nd, 2026 5:30 am
Arletta Pharma Solutions Appoints Steve van Os, MD, as Chief Medical Officer - Jun 19th, 2026 1:53 am
Organon and Samsung Bioepis Expand Agreement to Commercialize PYZCHIVA® (ustekinumab), a Biosimilar Referencing STELARA® (ustekinumab) in Canada - Jun 18th, 2026 4:00 am
Is TOFIDENCE’s Expanded CRS and COVID Label Altering The Investment Case For Organon (OGN)? - Jun 15th, 2026 6:17 pm
Organon (OGN) Stock After New TOFIDENCE Approval A Fresh Look At Valuation And Recovery Potential - Jun 15th, 2026 2:08 am
Organon Wins FDA Nod to Expand TOFIDENCE Use in Severe CRS & COVID-19 - Jun 12th, 2026 7:15 am
Organon Secures US Food and Drug Administration Approval Expanding Indications for TOFIDENCE® (tocilizumab-bavi) in Cytokine Release Syndrome (CRS) and Pediatric COVID-19 - Jun 10th, 2026 5:30 am
Organon Audit Cleared And New Data Put Valuation And Risks In Focus - May 25th, 2026 5:08 pm
Hanmi Pharmaceutical Partners with Organon to Export Combination Therapies to Southeast Asia - May 21st, 2026 3:06 am
India’s pharma industry is going global. But can it catch up to China? - May 13th, 2026 3:00 am
Organon Buyout By Sun Pharma Shifts Focus To Cash Value And Timing - May 7th, 2026 6:12 am
Lilly, Gilead lead pharma’s M&A boom - May 7th, 2026 2:52 am